HiFiBiO partners with Johnson & Johnson Innovation

Exploring New Antibody Discovery Platforms – While current antibody discovery technologies, such as hybridomas, are highly reliable, they are also inefficient in terms of percentage of antigen-specific B cells identified during screening. HiFiBiO and Janssen Biotech, Inc. are collaborating to evaluate the company’s single cell technology for genetically characterizing individual cells as a potential new antibody discovery platform. Validation activities include comparing a large repertoire of B-cell antibodies from a number of different tissues generated against a target antigen chosen by Janssen Research & Development, LLC.

Read the full press release

Leave a Reply